Portfolio company
Sitryx Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops oral small molecule therapies to treat patients with autoimmune and inflammatory diseases by regulating immune cell metabolism.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Sitryx
This biopharmaceutical company develops oral small molecule medicines that target immune cell metabolism to treat patients with chronic autoimmune and inflammatory diseases.
Promakhos
This company develops oral small-molecule immunotherapies that restore immune system function to treat patients with chronic inflammatory diseases.
Dualyx
This company develops immune-modulating therapies targeting regulatory T cells to treat patients with autoimmune diseases.
Promakhos Therapeutics
This company develops oral small molecule therapies to treat chronic inflammatory and autoimmune disorders for patients with conditions such as Crohn's disease.
Forward Therapeutics
The company develops oral small-molecule medicines for patients with chronic immunological and inflammatory disorders.
Matchpoint Therapeutics
This biotechnology company develops oral covalent small molecule medicines to treat patients with autoimmune and inflammatory diseases.
PsiThera
PsiThera develops oral small-molecule medicines for patients with immune and inflammatory diseases, using a physics-driven platform to target proteins traditionally requiring injections.
Immunic Therapeutics
The company develops oral therapies for chronic inflammatory and autoimmune diseases for patients with neurological and gastrointestinal conditions.